Reynders McVeigh Capital Management LLC Sells 1,534 Shares of Illumina, Inc. (NASDAQ:ILMN)

Reynders McVeigh Capital Management LLC trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 19.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,312 shares of the life sciences company’s stock after selling 1,534 shares during the quarter. Reynders McVeigh Capital Management LLC’s holdings in Illumina were worth $843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. Seeds Investor LLC increased its stake in shares of Illumina by 19.0% during the fourth quarter. Seeds Investor LLC now owns 2,796 shares of the life sciences company’s stock valued at $374,000 after purchasing an additional 447 shares in the last quarter. Sagespring Wealth Partners LLC bought a new position in Illumina during the 4th quarter valued at approximately $225,000. Townsquare Capital LLC raised its stake in Illumina by 23.5% during the fourth quarter. Townsquare Capital LLC now owns 16,196 shares of the life sciences company’s stock valued at $2,164,000 after buying an additional 3,087 shares during the last quarter. Rockefeller Capital Management L.P. boosted its holdings in Illumina by 6.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 185,220 shares of the life sciences company’s stock worth $24,751,000 after acquiring an additional 10,568 shares in the last quarter. Finally, Sterling Capital Management LLC grew its stake in shares of Illumina by 20.9% in the fourth quarter. Sterling Capital Management LLC now owns 17,118 shares of the life sciences company’s stock worth $2,287,000 after acquiring an additional 2,960 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Up 4.9 %

ILMN stock opened at $74.78 on Friday. The business’s 50-day moving average price is $88.58 and its 200-day moving average price is $122.32. The stock has a market cap of $11.85 billion, a P/E ratio of -9.74, a PEG ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ILMN. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their price target for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Royal Bank of Canada cut their price target on shares of Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday, April 8th. Citigroup decreased their price objective on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a report on Monday, April 7th. Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Finally, Guggenheim decreased their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Moderate Buy” and an average price target of $138.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.